11月20日，九洲药业跌2.09%，成交额4.87亿元。两融数据显示，当日九洲药业获融资买入额6575.20万 元，融资偿还5960.66万元，融资净买入614.55万元。截至11月20日，九洲药业融资融券余额合计6.20亿 元。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 截至9月30日，九洲药业股东户数5.92万，较上期增加10.22%；人均流通股15035股，较上期减少 9.27%。2025年1月-9月，九洲药业实现营业收入41.60亿元，同比增长4.92%；归母净利润7.48亿元，同 比增长18.51%。 分红方面，九洲药业A股上市后累计派现21.83亿元。近三年，累计派现12.45亿元。 机构持仓方面，截止2025年9月30日，九洲药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2036.80万股，相比上期增加781 ...

截至发稿，葛兰累计任职时间10年293天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 109.26%， 任职期间最差基金回报-35.13%。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）三季度 增持397.67万股，持有股数1740.3万股，占流通股的比例为1.96%。根据测算，今日浮盈赚取约1879.52 万元。连续4天上涨期间浮盈赚取1583.67万元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益24.47%， 同类排名3925/8140；近一年收益13.31%，同类排名4906/8056；成立以来收益114.81%。 11月14日，九洲药业涨5.31% ...

Core Viewpoint - Jiuzhou Pharmaceutical's stock has shown significant performance, with a year-to-date increase of 53.80%, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92%. The net profit attributable to shareholders was 748 million yuan, reflecting an 18.51% increase compared to the previous year [2]. - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3]. Stock Market Activity - As of November 12, Jiuzhou Pharmaceutical's stock price was 20.28 yuan per share, with a trading volume of 283 million yuan and a turnover rate of 1.59%. The total market capitalization stood at 18.038 billion yuan [1]. - The stock has seen a net inflow of 10.22 million yuan from major funds, with significant buying activity noted in large orders [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 59,200, a rise of 10.22%. The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2][3]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Medical Health Mixed A, both of which increased their holdings [3].

Core Viewpoint - Fujilai (301258) announced a delay in the implementation of its "Annual Production of 289 Tons of Specialty Raw Materials Expansion Project" to December 31, 2026, due to extended project review processes and the need for compliance with current standards [1] Group 1: Project Delay - The delay in the project is attributed to the need for identifying and proposing modifications to existing facilities and production lines to meet current standards [1] - The company aims to ensure the technological advancement, operational stability, and long-term benefits of the project by investing additional time in technical validation and optimization [1] Group 2: Investment Adjustment - Fujilai plans to increase the total investment for the "Fujilai (Shandong) Specialty Raw Materials and Intermediates CMO/CDMO Construction Project" from 250 million yuan to 310 million yuan, utilizing excess fundraising for the additional investment [1] - The internal investment structure of the project will also be adjusted accordingly [1]

Core Points - Fujilai announced an increase in the total investment for the "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" from 250 million to 310 million yuan, utilizing excess raised funds for the additional investment [2] Group 1 - The fifth meeting of the fourth board of directors is scheduled for November 10, 2025, to review the proposal regarding the increase in construction content and additional investment amount for certain fundraising projects [2] - The internal investment structure of the Shandong project will also be adjusted as part of this proposal [2] - The proposal is subject to approval by the shareholders' meeting [2]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 46.67% but a recent decline in the last five trading days by 3.30% [1] Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92% [2] - The net profit attributable to the parent company for the same period was 748 million yuan, showing an increase of 18.51% year-on-year [2] Stock Market Activity - As of November 5, Jiuzhou Pharmaceutical's stock price was 19.34 yuan per share, with a market capitalization of 17.202 billion yuan [1] - The stock has seen a net outflow of main funds amounting to 21.4868 million yuan, with significant selling pressure observed [1] Shareholder Information - As of September 30, 2025, the number of Jiuzhou Pharmaceutical's shareholders increased to 59,200, up by 10.22% from the previous period [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 20.368 million shares, an increase of 7.8125 million shares [3] Dividend Distribution - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3]

Core Viewpoint - Jiuzhou Pharmaceutical is a well-established manufacturer of chemical raw materials and pharmaceutical intermediates in China, with strong technical capabilities and scale advantages in the custom drug development and production service sector [1] Financial Performance - In Q3 2025, Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan, ranking 5th in the industry out of 29 companies, surpassing the industry average of 2.547 billion yuan and the median of 607 million yuan, but still lagging behind the top competitors WuXi AppTec at 32.857 billion yuan and Kanglong Chemical at 10.086 billion yuan [2] - The company's net profit for the same period was 749 million yuan, also ranking 5th in the industry, above the average of 585 million yuan but below the median of 80.706 million yuan, with WuXi AppTec leading at 12.206 billion yuan and Tigermed at 1.092 billion yuan [2] Financial Ratios - As of Q3 2025, Jiuzhou Pharmaceutical's debt-to-asset ratio was 17.67%, down from 21.67% year-on-year and below the industry average of 22.79%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 37.55%, an increase from 34.75% year-on-year, and close to the industry average of 37.70%, reflecting improved profitability [3] Executive Compensation - The chairman, Hua Lirong, received a salary of 1.985 million yuan in 2024, a decrease of 528,000 yuan from 2023 [4] - The president, Mei Yijiang, earned 3.276 million yuan in 2024, down 339,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.22% to 59,200, while the average number of shares held per shareholder decreased by 9.27% to 15,000 [5] - Major shareholders include Hong Kong Central Clearing Limited and various mutual funds, with notable increases in holdings from some shareholders [5] Business Highlights - The CDMO business continues to grow rapidly, driven by strong overseas demand and an increase in key clinical batches and NDA projects [5][6] - The TIDES business is progressing well, with the second phase of peptide production capacity set to launch [5][6] - The company is expanding its global footprint, with significant growth in the Japanese, Korean, and U.S. markets [5] Future Projections - Revenue forecasts for Jiuzhou Pharmaceutical are 5.57 billion yuan, 5.83 billion yuan, and 6.29 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 949 million yuan, 1.052 billion yuan, and 1.207 billion yuan for the same years [5][6]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 41.44% but a recent decline of 5.71% over the past five trading days [1] Financial Performance - For the period of January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92%. The net profit attributable to shareholders was 748 million yuan, reflecting an 18.51% increase compared to the previous year [2] Stock Market Activity - As of October 23, Jiuzhou Pharmaceutical's stock price was 18.65 yuan per share, with a market capitalization of 16.588 billion yuan. The stock saw a net outflow of 10.89 million yuan in principal funds, with significant selling pressure from large orders [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 51.1 million yuan on April 15 [1] Shareholder Information - As of September 30, 2025, Jiuzhou Pharmaceutical had 59,200 shareholders, an increase of 10.22% from the previous period. The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable increases in holdings for some [3] Dividend Distribution - Since its A-share listing, Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends, with 1.245 billion yuan distributed over the past three years [3]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 43.64% but a recent decline of 8.63% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92% [2] - The net profit attributable to shareholders for the same period was 748 million yuan, reflecting an 18.51% increase year-on-year [2] Stock Market Activity - As of October 22, Jiuzhou Pharmaceutical's stock price was 18.94 yuan per share, with a market capitalization of 16.846 billion yuan [1] - The stock has seen a net outflow of 33.85 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Information - As of September 30, 2025, the number of Jiuzhou Pharmaceutical's shareholders increased by 10.22% to 59,200 [2] - The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2] Dividend Distribution - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 20.368 million shares, an increase of 7.8125 million shares from the previous period [3] - The top ten circulating shareholders include various funds, indicating a diverse institutional interest in the company [3]

Core Insights - On October 20, Jiuzhou Pharmaceutical experienced a slight decline of 0.05% with a trading volume of 444 million yuan, indicating a stable market presence [1] - As of September 30, Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, which is an 18.51% increase compared to the previous year [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3] Financing and Trading Activity - On October 20, Jiuzhou Pharmaceutical had a net financing purchase of 1.664 million yuan, with a total financing balance of 528 million yuan, representing 3.14% of its market capitalization [1] - The company’s financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - In terms of securities lending, Jiuzhou Pharmaceutical had a low short-selling balance of 2.3136 million yuan, which is below the 50th percentile of the past year, suggesting limited bearish sentiment [1] Shareholder and Institutional Holdings - As of September 30, the number of Jiuzhou Pharmaceutical shareholders increased to 59,200, a rise of 10.22%, while the average number of shares held per shareholder decreased by 9.27% to 15,035 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 20.368 million shares, an increase of 7.8125 million shares from the previous period [3] - The sixth largest shareholder, China Europe Medical Health Mixed A, holds 17.403 million shares, up by 3.9767 million shares, while the seventh largest, Huabao CSI Medical ETF, reduced its holdings by 2.5629 million shares to 15.2225 million shares [3]